Senior Fellow Nathan Furukawa recently published an article on “National Trends in Drug Payments for HIV Preexposure Prophylaxis in the United States” in the journal Annals of Internal Medicine. In this retrospective study, the distribution of cost for PrEP was tracked across the country between the years of 2014 and 2018. PrEP, or Preexposure Prophylaxis, is the widely used HIV prevention drug. This study used data from the IQVIA Longitudinal Prescriptions database, giving them data from 90% of retail prescriptions. This retrospective study found that while the amount of prescriptions increased, so did the costs, both in terms of the average total costs and the out of pocket payments. This is important because the increase in cost may prevent PrEP expansion. Read more here.